Dashboard
Manage Tickers

REGNREGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 1,037.08 $ 9.97 (0.97 %)    

Friday, 14-Jun-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 1036.52
$ 1,016.44
$ 1,036.40 x 200
$ 1,037.39 x 100
$ 1,016.44 - $ 1,041.56
$ 684.81 - $ 1,042.66
353,915
na
119.3B
$ 0.53
$ 30.93
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-05-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-06-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-07-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-08-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-07-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-07-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-11-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regenerons-dupixent-copd-sales-to-reach-20b-by-2026-analyst-sees-larger-addressable-market
Regeneron's Dupixent COPD Sales To Reach $...
06/13/2024 13:39:02

Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.

rbc-capital-maintains-outperform-on-regeneron-pharmaceuticals-raises-price-target-to-1229
RBC Capital Maintains Outperform on Regene...
06/12/2024 11:53:45

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...

peering-into-regeneron-pharmaceuticalss-recent-short-interest
Peering Into Regeneron Pharmaceuticals's R...
06/11/2024 20:45:11

Core News & Articles
Regeneron Anticipates Obesity Drug Trial D...
06/11/2024 12:23:38

- Goldman Sachs Conference

Core News & Articles
Regeneron, Sanofi Report FDA Approval Of K...
06/11/2024 11:02:06

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside
Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

whats-going-on-with-fibrogen-stock-tuesday
What's Going On With FibroGen Stock Tuesday?
06/04/2024 18:27:03

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...

competitor-analysis-evaluating-regeneron-pharmaceuticals-and-competitors-in-biotechnology-industry
Competitor Analysis: Evaluating Regeneron ...
06/04/2024 15:00:55

navigating-14-analyst-ratings-for-regeneron-pharmaceuticals
Navigating 14 Analyst Ratings For Regenero...
06/04/2024 14:01:20

rbc-capital-maintains-outperform-on-regeneron-pharmaceuticals-raises-price-target-to-1200
RBC Capital Maintains Outperform on Regene...
06/04/2024 13:53:13

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...

fibrogen-stock-is-surging-after-the-bell-whats-going-on
FibroGen Stock Is Surging After The Bell: ...
06/03/2024 20:48:42

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investiga...

Core News & Articles
FibroGen Inks Clinical Trial Supply Agreem...
06/03/2024 20:09:25

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combi...

heres-how-much-100-invested-in-regeneron-pharmaceuticals-10-years-ago-would-be-worth-today
Here's How Much $100 Invested In Regeneron...
06/03/2024 18:00:24

fda-extends-review-deadline-for-regeneronsanofis-dupixent-for-smokers-lungs-disease
FDA Extends Review Deadline For Regeneron/...
05/31/2024 13:23:50

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...

Core News & Articles
Sanofi And Regeneron Pharmaceuticals' Dupi...
05/31/2024 06:34:29

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...

Core News & Articles
FDA Extends Priority Review Deadline For R...
05/31/2024 05:55:36

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...

whats-going-on-with-biohaven-stock-wednesday
What's Going On With Biohaven Stock Wednes...
05/29/2024 16:03:45

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stolen-in-data-breach-in-february
After UnitedHealth Cyberattack, Drug Distr...
05/24/2024 16:00:24

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...

regn---analyzing-regeneron-pharmaceuticalss-short-interest
(REGN) - Analyzing Regeneron Pharmaceutica...
05/20/2024 19:15:23

Core News & Articles
Regeneron Pharmaceuticals And Sanofi Prese...
05/20/2024 18:17:57

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)